New hope for kids with tough cancers: immunotherapy drug shows promise
NCT ID NCT02332668
First seen Apr 04, 2026 · Last updated May 01, 2026 · Updated 4 times
Summary
This study tests pembrolizumab, an immunotherapy that helps the immune system fight cancer, in children aged 6 months to 18 years with advanced melanoma, solid tumors, or lymphomas that have spread, returned, or not responded to prior treatment. The goal is to see if the drug can shrink or control the cancer. About 370 participants are enrolled, and the study is still recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-••••
Locations
-
Call for Information (Investigational Site 0019)
RECRUITINGAurora, Colorado, 80045, United States
-
Call for Information (Investigational Site 0026)
RECRUITINGBoston, Massachusetts, 02445, United States
-
Call for Information (Investigational Site 0031)
RECRUITINGNew York, New York, 10032, United States
-
Call for Information (Investigational Site 0032)
RECRUITINGCincinnati, Ohio, 45229, United States
-
Call for Information (Investigational Site 0054)
RECRUITINGDallas, Texas, 75235, United States
-
Call for Information (Investigational Site 0070)
RECRUITINGFargo, North Dakota, 58102, United States
-
Call for Information (Investigational Site 0071)
RECRUITINGSioux Falls, South Dakota, 57117, United States
-
MSD Brasil
RECRUITINGSão Paulo, Brazil
Contact Phone: •••-•••-••••
-
MSD France
RECRUITINGParis, France
Contact Phone: •••-•••-••••
-
MSD Italia S.r.l.
RECRUITINGRome, Italy
Contact Phone: •••-•••-••••
-
MSD Korea LTD
RECRUITINGSeoul, 4130, South Korea
Contact Phone: •••-•••-••••
-
MSD Sharp & Dohme GmbH
RECRUITINGMünchen, Germany
Contact Phone: •••-•••-••••
-
MSD Sweden
RECRUITINGStockholm, Sweden
Contact Phone: •••-•••-••••
-
Merck Sharp & Dohme BV
RECRUITINGHaarlem, Netherlands
Contact Phone: •••-•••-••••
-
Merck Sharp & Dohme Co. Ltd.
RECRUITINGHod HaSharon, Israel
Contact Phone: •••-•••-••••
-
Merck Sharp & Dohme Lda.
RECRUITINGPaço de Arcos, Portugal
Contact Phone: •••-•••-••••
-
Merck Sharp & Dohme Ltd.
RECRUITINGLondon, United Kingdom
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.